drugset / Trial / NCT05327361

LiftActiv B3 in Post Inflammatory Hyperpigmentation (PIHP)

NCT05327361 ↗

Phase 2 Terminated 13 enrolled University of Miami Vichy Laboratoires · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this research study is to measure the depigmenting effect of a serum product called Liftactiv B3 in patients with mild to moderate facial PIHP (Post Inflammatory Hyper Pigmentation)

Timeline

Start
2022-03-22
Primary completion
2023-01-17
Completion
2023-03-06

Outcome

Outcome not reported

Stopped (Enrollment): “Enrollment timeline ended”

Drugs

EvaluationDrugModalityDoseRoute
Subject Liftactiv B3 Unknown — Topical